Shockwave C 2+ Debut Joins Packed Shockwave Agenda at Transcatheter Cardiovascular Therapeutics Conference in San Francisco
SANTA CLARA, Calif., Oct. 20, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today the planned U.S. introduction of the Shockwave C 2+ Coronary Intravascular Lithotripsy (IVL) catheter following approval by the U.S. Food and Drug Administration. The Shockwave C 2+ catheter provides 50 percent more pulses per catheter than the Shockwave C 2 catheter that was approved in the U.S. in 2021. The enhanced […]
Click here to visit source. finance.yahoo.com